Sanofi has completed its acquisition of Amunix Pharmaceuticals, adding a promising pipeline of T-cell engagers and cytokine therapies.
The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics.
The technology platform is highly complementary to Sanofi’s existing R&D platforms and supports Sanofi’s efforts to accelerate and expand its contributions to innovative medicines for oncology patients, with approximately 20 molecules currently in development.
Weil, Gotshal & Manges LLP is acting as Sanofi’s legal counsel. Centerview Partners LLC is acting as financial advisor to Amunix and Fenwick & West LLP is acting as its legal counsel.
In December it was announced that Sanofi would acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones.